{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T15:02:38Z","timestamp":1764687758047,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13048-017-0373-9","type":"journal-article","created":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T22:54:03Z","timestamp":1515106443000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Suitability assessment of baseline concentration of MMP3, TIMP3, HE4 and CA125 in the serum of patients with ovarian cancer"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4727-7763","authenticated-orcid":false,"given":"Aneta","family":"Cymbaluk-P\u0142oska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Chudecka-G\u0142az","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Pius-Sadowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogus\u0142aw","family":"Machali\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janusz","family":"Menkiszak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Sompolska-Rzechu\u0142a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,5]]},"reference":[{"issue":"6","key":"373_CR1","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1200\/JCO.1989.7.6.769","volume":"7","author":"JC van Houwelingen","year":"1989","unstructured":"van Houwelingen JC, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Neijt JP. Predictability of the survival of patients with advanced ovarian cancer. J Clin Oncol. 1989;7(6):769\u201373.","journal-title":"J Clin Oncol"},{"issue":"2","key":"373_CR2","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1006\/gyno.1998.5074","volume":"70","author":"P Hoskins","year":"1998","unstructured":"Hoskins P, Tu D, James K, Pater J, Koski B. Factors predictive of survival after first relapse or progression in advanced epithelial ovarian carcinoma: a prediction tree analysis-derived model with test and validation groups. Gynecol Oncol. 1998;70(2):224\u201330.","journal-title":"Gynecol Oncol"},{"issue":"7","key":"373_CR3","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1054\/bjoc.2001.2030","volume":"85","author":"TG Clark","year":"2001","unstructured":"Clark TG, Stewart ME, Altman DG, Gabra H, Smyth JFA. prognostic model for ovarian cancer. Br J Cancer. 2001;85(7):944\u201352.","journal-title":"Br J Cancer"},{"issue":"3","key":"373_CR4","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ygyno.2014.06.021","volume":"134","author":"HS van Meurs","year":"2014","unstructured":"van Meurs HS, Schuit E, Horlings HM, van der Velden J, van Driel WJ, Mol BW, et al. Development and internal validation of a prognostic model to predict recurrence free survival in patients with adult granulosa cell tumors of the ovary. Gynecol Oncol. 2014;134(3):498\u2013504.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"373_CR5","doi-asserted-by":"crossref","first-page":"e62023","DOI":"10.1371\/journal.pone.0062023","volume":"8","author":"C Zhang","year":"2013","unstructured":"Zhang C, Li C, Zhu M, Zhang Q, Xie Z, Niu G, et al. Meta-analysis of MMP2, MMP3, and MMP9 promoter polymorphisms and head and neck cancer risk. PLoS One. 2013;8(4):e62023.","journal-title":"PLoS One"},{"issue":"1","key":"373_CR6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3892\/br.2016.682","volume":"5","author":"SU Wei","year":"2016","unstructured":"Wei SU, Li H, Zhang B. The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer. Biomed Rep. 2016;5(1):41\u20134.","journal-title":"Biomed Rep"},{"issue":"5","key":"373_CR7","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.3892\/ol.2016.5058","volume":"12","author":"A Chudecka-Glaz","year":"2016","unstructured":"Chudecka-Glaz A, Cymbaluk-Ploska A, Luterek-Puszynska K, Menkiszak J. Diagnostic usefulness of the risk of ovarian malignancy algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125. Oncol Lett. 2016;12(5):3101\u201314.","journal-title":"Oncol Lett"},{"issue":"4","key":"373_CR8","first-page":"1865","volume":"36","author":"A Pelissier","year":"2016","unstructured":"Pelissier A, Bonneau C, Chereau E, DE LA Motte Rouge T, Fourchotte V, Darai E, et al. Dynamic analysis of CA125 decline during Neoadjuvant chemotherapy in patients with epithelial ovarian cancer as a predictor for platinum sensitivity. Anticancer Res. 2016;36(4):1865\u201371.","journal-title":"Anticancer Res"},{"issue":"6","key":"373_CR9","first-page":"315","volume":"31","author":"HS Kim","year":"2008","unstructured":"Kim HS, Park NH, Chung HH, Kim JW, Song YS, Kang SB. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer. Onkologie. 2008;31(6):315\u201320.","journal-title":"Onkologie"},{"issue":"3","key":"373_CR10","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ygyno.2012.09.003","volume":"127","author":"D Trudel","year":"2012","unstructured":"Trudel D, Tetu B, Gregoire J, Plante M, Renaud MC, Bachvarov D, et al. Human epididymis protein 4 (HE4) and ovarian cancer prognosis. Gynecol Oncol. 2012;127(3):511\u20135.","journal-title":"Gynecol Oncol"},{"issue":"8","key":"373_CR11","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1097\/IGC.0000000000000218","volume":"24","author":"E Piovano","year":"2014","unstructured":"Piovano E, Attamante L, Macchi C, Cavallero C, Romagnolo C, Maggino T, et al. The role of HE4 in ovarian cancer follow-up: a review. Int J Gynecol Cancer. 2014;24(8):1359\u201365.","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"373_CR12","first-page":"2597","volume":"17","author":"A Cymbaluk-Ploska","year":"2016","unstructured":"Cymbaluk-Ploska A, Chudecka-Glaz A, Surowiec A, Pius-Sadowska E, Machalinski B, Menkiszak J. MMP3 in comparison to CA 125, HE4 and the ROMA algorithm in differentiation of ovarian tumors. Asian Pac J Cancer Prev. 2016;17(5):2597\u2013603.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"10","key":"373_CR13","doi-asserted-by":"crossref","first-page":"13240","DOI":"10.3390\/ijms131013240","volume":"13","author":"L Herszenyi","year":"2012","unstructured":"Herszenyi L, Hritz I, Lakatos G, Varga MZ, Tulassay Z. The behavior of matrix metalloproteinases and their inhibitors in colorectal cancer. Int J Mol Sci. 2012;13(10):13240\u201363.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"373_CR14","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1006\/cbir.2000.0647","volume":"25","author":"RR Baruch","year":"2001","unstructured":"Baruch RR, Melinscak H, Lo J, Liu Y, Yeung O, Hurta RA. Altered matrix metalloproteinase expression associated with oncogene-mediated cellular transformation and metastasis formation. Cell Biol Int. 2001;25(5):411\u201320.","journal-title":"Cell Biol Int"},{"issue":"6","key":"373_CR15","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3892\/ol.2011.391","volume":"2","author":"JW Choi","year":"2011","unstructured":"Choi JW, Ahn SE, Rengaraj D, Seo HW, Lim W, Song G, et al. Matrix metalloproteinase 3 is a stromal marker for chicken ovarian cancer. Oncol Lett. 2011;2(6):1047\u201351.","journal-title":"Oncol Lett"},{"issue":"12","key":"373_CR16","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.2174\/138161209787846711","volume":"15","author":"H Denys","year":"2009","unstructured":"Denys H, Braems G, Lambein K, Pauwels P, Hendrix A, De Boeck A, et al. The extracellular matrix regulates cancer progression and therapy response: implications for prognosis and treatment. Curr Pharm Des. 2009;15(12):1373\u201384.","journal-title":"Curr Pharm Des"},{"issue":"5","key":"373_CR17","first-page":"417","volume":"24","author":"S Ozalp","year":"2003","unstructured":"Ozalp S, Tanir HM, Yalcin OT, Kabukcuoglu S, Oner U, Uray M. Prognostic value of matrix metalloproteinase-9 (gelatinase-B) expression in epithelial ovarian tumors. Eur J Gynaecol Oncol. 2003;24(5):417\u201320.","journal-title":"Eur J Gynaecol Oncol"},{"issue":"6","key":"373_CR18","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s00404-012-2456-6","volume":"286","author":"X Hu","year":"2012","unstructured":"Hu X, Li D, Zhang W, Zhou J, Tang B, Li L. Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion. Arch Gynecol Obstet. 2012;286(6):1537\u201343.","journal-title":"Arch Gynecol Obstet"},{"issue":"13","key":"373_CR19","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0959-8049(03)00427-1","volume":"39","author":"L Manenti","year":"2003","unstructured":"Manenti L, Paganoni P, Floriani I, Landoni F, Torri V, Buda A, et al. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer. 2003;39(13):1948\u201356.","journal-title":"Eur J Cancer"},{"issue":"5","key":"373_CR20","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.humpath.2015.01.014","volume":"46","author":"P Desmeules","year":"2015","unstructured":"Desmeules P, Trudel D, Turcotte S, Sirois J, Plante M, Gregoire J, et al. Prognostic significance of TIMP-2, MMP-2, and MMP-9 on high-grade serous ovarian carcinoma using digital image analysis. Hum Pathol. 2015;46(5):739\u201345.","journal-title":"Hum Pathol"},{"issue":"4","key":"373_CR21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10495-014-1076-y","volume":"20","author":"JH Qi","year":"2015","unstructured":"Qi JH, Anand-Apte B. Tissue inhibitor of metalloproteinase-3 (TIMP3) promotes endothelial apoptosis via a caspase-independent mechanism. Apoptosis. 2015;20(4):523\u201334.","journal-title":"Apoptosis"},{"key":"373_CR22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejca.2015.09.014","volume":"53","author":"AM Das","year":"2016","unstructured":"Das AM, Koljenovic S, Oude Ophuis CM, van der Klok T, Galjart B, Nigg AL, et al. Association of TIMP3 expression with vessel density, macrophage infiltration and prognosis in human malignant melanoma. Eur J Cancer. 2016;53:135\u201343.","journal-title":"Eur J Cancer"},{"issue":"8","key":"373_CR23","doi-asserted-by":"crossref","first-page":"e106161","DOI":"10.1371\/journal.pone.0106161","volume":"9","author":"X Gu","year":"2014","unstructured":"Gu X, Fu M, Ding Y, Ni H, Zhang W, Zhu Y, et al. TIMP-3 expression associates with malignant behaviors and predicts favorable survival in HCC. PLoS One. 2014;9(8):e106161.","journal-title":"PLoS One"},{"issue":"4","key":"373_CR24","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3892\/or.2011.1608","volume":"27","author":"JL Brun","year":"2012","unstructured":"Brun JL, Cortez A, Lesieur B, Uzan S, Rouzier R, Darai E. Expression of MMP-2, \u22127, \u22129, MT1-MMP and TIMP-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer. Oncol Rep. 2012;27(4):1049\u201357.","journal-title":"Oncol Rep"},{"issue":"1","key":"373_CR25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ygyno.2009.09.019","volume":"116","author":"WD Kang","year":"2010","unstructured":"Kang WD, Choi HS, Kim SM. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer. Gynecol Oncol. 2010;116(1):57\u201360.","journal-title":"Gynecol Oncol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-017-0373-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T21:40:58Z","timestamp":1570570858000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-017-0373-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,5]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["373"],"URL":"https:\/\/doi.org\/10.1186\/s13048-017-0373-9","relation":{},"ISSN":["1757-2215"],"issn-type":[{"type":"electronic","value":"1757-2215"}],"subject":[],"published":{"date-parts":[[2018,1,5]]},"article-number":"1"}}